Table 3 Prostate-specific antigen data
From: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer
Patient | Screening PSA (ng ml−1) | PSA nadir (ng ml−1) | % PSA decline a | Pretrial PSA vel. (ng ml−1 month−1) | Trial PSA vel. (ng ml−1 month−1) |
|---|---|---|---|---|---|
1b | 87 | DNF | — | 19 (22%) | 9 (10%) |
2 | 111 | DNF | — | 31 (28%) | 4 (4%) |
3 | 3302 | 1256 | 62 | 514 (16%) | −2046 (−62%) |
4b | 152 | 35 | 77 | 27 (18%) | −19 (−13%) |
5 | 322 | 178 | 45 | 20 (6%) | −104 (−32%) |
6 | 170 | 170 | 0 | 8 (5%) | −4 (2%) |
7b | 86 | 65 | 24 | 17 (20%) | −14 (−16%) |
8b | 46 | DNF | — | 5 (11%) | 1 (2%) |
9 | 56 | 50 | 11 | 25 (45%) | −6 (−11%) |
10 | 69 | NA | — | NA | NA |
11b | 74 | DNF | — | 8 (11%) | 7 (9%) |
12 | 585 | 399 | 32 | 244 (42%) | −132 (−23%) |
13 | 102 | DNF | — | 15 (15%) | 16 (16%) |
14b | 25 | DNF | — | 13 (52%) | 2 (8%) |
15 | 81 | DNF | — | 8 (10%) | 11 (14%) |
16 | 143 | 140 | 2 | 4 (3%) | −20 (−14%) |
17 | 65 | NA | — | 18 (28%) | NA |
18 | 400 | NA | — | 133 (33%) | NA |
19 | 400 | NA | — | 43 (11%) | NA |
20b | 14 | 7 | 50 | 3 (21%) | −5 (−36%) |
